YH239-EE is primarily used in preclinical research as a potent and selective inhibitor of the MDM2-p53 protein-protein interaction. By disrupting this interaction, it activates the p53 tumor suppressor pathway, making it a valuable tool in cancer research, particularly in studies involving tumors with wild-type p53. It has shown promising results in inducing apoptosis in cancer cell lines and is used to investigate therapeutic strategies for cancers such as leukemia, melanoma, and certain solid tumors. Its cell-permeable and orally bioavailable properties enhance its utility in animal models for evaluating antitumor efficacy and pharmacokinetics.